Ownership and insider activity for Boundless Bio, Inc. (BOLD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers.
Price
| Price | $2.82 |
| Market Cap | $63M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $36.4M | $39.0M | $144.3M | $34.3M | $11.0M | $23.7M | $26.6M | $17.9M |
| Short-term Investments | $68.5M | $94.6M | $270.0M | $38.7M | $55.8M | $97.0M | $125.5M | $89.7M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $108.4M | $137.0M | $419.8M | $74.6M | $68.0M | $124.2M | $154.4M | $109.6M |
| Property, Plant & Equipment | $18.9M | $24.4M | $32.1M | $3.1M | $7.7M | $4.6M | $51.4M | $46.9M |
| Goodwill | $3.6M | $3.6M | $3.6M | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $8.0M | $8.0M | $8.0M | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $142.1M | $178.7M | $472.6M | $113.7M | $76.8M | $129.9M | $206.4M | $157.1M |
| Accounts Payable | $2.4M | $3.9M | $8.1M | $1.1M | $1.4M | $2.2M | $1.3M | $1.5M |
| Short-term Debt | $265000 | $4.6M | $2.3M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $12.6M | $17.7M | $23.9M | $3.9M | $7.7M | $9.4M | $8.1M | $12.5M |
| Long-term Debt | $2.5M | $2.5M | $4.7M | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $22.7M | $22.1M | $29.8M | $151.9M | $158.5M | $257.0M | $55.8M | $58.4M |
| Retained Earnings | -$100.4M | -$190.6M | -$319.5M | -$40.8M | -$86.7M | -$136.1M | -$201.5M | -$259.7M |
| Total Equity | $119.4M | $156.6M | $442.8M | -$38.2M | -$81.7M | -$127.1M | $150.6M | $98.7M |
| Total Debt | $2.8M | $7.2M | $7.1M | $377000 | $5.2M | $2.2M | $47.6M | $49.0M |
| Net Debt | -$102.1M | -$126.4M | -$407.2M | -$72.7M | -$61.5M | -$118.6M | -$104.5M | -$58.5M |
| Working Capital | $95.9M | $119.3M | $395.9M | $70.7M | $60.3M | $114.8M | $146.3M | $97.1M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 9.48 |
| Piotroski F-Score | 1 |
| Altman Z-Score | -2.63 |
Profitability
| Return on Equity | -70.89% |
| Return on Invested Capital | -103.08% |
| Return on Assets | -86.80% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ANTX · INTS · ITRM · NXTC · PLUR · PSTV · QTTB
Explore sector: Healthcare · Biotechnology
More sections of BOLD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks